



Agenus to Present at the 4th Annual Cancer Immunotherapy Conference

March 26, 2014

Agenus Inc. (Nasdaq: AGEN) today announced that Robert Stein, MD, PhD, Chief Scientific Officer of Agenus, will be presenting on Agenus' checkpoint modulator portfolio and immuno-oncology strategy at the 4th Annual Cancer Immunotherapy Conference at the New York Academy of Medicine in New York City. On March 27, 2014, a presentation on Checkpoint Modulators is scheduled for 8:30 am Eastern Time and a corporate presentation is scheduled for 2:15 pm Eastern Time

Additionally, Dr. Stein will be participating on several panels, including:

- 9:30 am -10:15 am: Emerging Role of Combination Tumor Immunotherapies
- 11:45 pm -12:30 pm: Autologous Immunotherapies
- 4:00 pm - 4:30 pm: Immunotherapies for Solid Tumors

The corporate presentation will be webcast and accessible from the company's website at www.agenusbio.com/webcast/.

About Agenus

Agenus is a biopharmaceutical company developing a portfolio of immuno-oncology candidates, including checkpoint modulators, heat shock protein vaccines and adjuvants. The company's proprietary discovery engine Retrocyte Display® is designed to rapidly generate high quality therapeutic antibody drug candidates using a high-throughput approach incorporating IgG format human antibody libraries expressed in mammalian B-lineage cells. A portfolio of checkpoint modulator programs, including GITR, OX40 agonists and CTLA-4, PD-1, LAG-3 and TIM-3 antagonists, is advancing in preclinical development. The company's heat shock protein vaccines for cancer and infectious disease are in Phase 2 studies. Agenus' QS-21 Stimulon® adjuvant platform is extensively partnered with GlaxoSmithKline and Janssen and includes several candidates in Phase 3 trials. Among Agenus and its partners, 23 programs are in clinical development. For more information, please visit www.agenusbio.com, or connect with the company on Facebook, LinkedIn, Twitter and Google+.

Forward-Looking Statement

This press release contains forward-looking statements, including statements regarding research and development activities of the Company and its licensees. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our Annual Report on Form 10-K filed with the Securities and Exchange Commission for the period ended December 31, 2013. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this document, and Agenus undertakes no obligation to update or revise the statements. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Agenus' business is subject to substantial risks and uncertainties, including those identified above. When evaluating Agenus' business and securities, investors should give careful consideration to these risks and uncertainties.

QS-21 Stimulon and Retrocyte Display are registered trademarks of Agenus and its subsidiaries.